Quidel (QDEL) & Intellia Therapeutics (NTLA) Critical Survey

Share on StockTwits

Quidel (NASDAQ: QDEL) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Earnings and Valuation

This table compares Quidel and Intellia Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quidel $277.74 million 9.23 -$8.16 million ($0.07) -977.86
Intellia Therapeutics $26.12 million 45.19 -$67.54 million ($1.88) -14.57

Quidel has higher revenue and earnings than Intellia Therapeutics. Quidel is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Quidel and Intellia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quidel 3.08% 12.54% 4.75%
Intellia Therapeutics -278.64% -31.80% -24.41%

Risk and Volatility

Quidel has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 3.21, indicating that its stock price is 221% more volatile than the S&P 500.

Institutional & Insider Ownership

90.2% of Quidel shares are owned by institutional investors. Comparatively, 60.7% of Intellia Therapeutics shares are owned by institutional investors. 16.7% of Quidel shares are owned by insiders. Comparatively, 12.8% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Quidel and Intellia Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quidel 0 0 6 2 3.25
Intellia Therapeutics 0 2 7 0 2.78

Quidel presently has a consensus price target of $58.83, indicating a potential downside of 14.05%. Intellia Therapeutics has a consensus price target of $34.83, indicating a potential upside of 27.18%. Given Intellia Therapeutics’ higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Quidel.


Quidel beats Intellia Therapeutics on 10 of the 15 factors compared between the two stocks.

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

About Intellia Therapeutics

Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply